Renagel

Sevelamer

Clinical data
Trade names	Renagel, Renvela
AHFS/Drugs.com	Monograph
MedlinePlus	a601248
Pregnancy category	AU: B3 US: C (Risk not ruled out)
Routes of administration	oral
ATC code	V03AE02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	0%
Excretion	faecal 100%
Identifiers
IUPAC name poly(allylamine- co-N,N'-diallyl-1,3-diamino-2-hydroxypropane)
CAS Number	52757-95-6 Y
PubChem CID	3085017
DrugBank	DB00658 N
ChemSpider	2341997 N
UNII	941N5DUU5C
KEGG	D08512 Y
ChEMBL	CHEMBL1201492 N
ECHA InfoCard	100.207.865
Chemical and physical data
Formula	[(C3H7N)a+b.(C9H17N2O)c]m where a+b:c = 9:1
Molar mass	variable
NY (what is this?)

Sevelamer (rINN) (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. Sevelamer was invented and developed by GelTex Pharmaceuticals. Sevelamer is currently marketed by Sanofi under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).

Sevelamer consists of polyallylamine that is crosslinked with epichlorohydrin. The marketed form sevelamer hydrochloride is a partial hydrochloride salt being present as approximately 40% amine hydrochloride and 60% sevelamer base. The amine groups of sevelamer become partially protonated in the intestine and interact with phosphate ions through ionic and hydrogen bonding.

...
Wikipedia